WHO Launches First Clinical Trial of Ebola Vaccine Amid DR Congo Outbreak
The World Health Organization (WHO) has initiated its first clinical trial of an Ebola vaccine during the ongoing outbreak in the Democratic Republic of Congo (DRC), marking a significant step in the global response to the health crisis.
WHO Director-General Tedros Ghebreyesus announced the development in a post on his official X handle on Friday, following the vaccination of the first participants in Bunia, located in the country’s northeastern Ituri province.
The trial, named Tumaini — which means “hope” in Swahili — will assess whether vaccine candidates can protect against the Bundibugyo strain of the Ebola virus, for which no vaccine has yet been approved.
“Science gives us hope. Today, in Bunia, DRC, the first participants were vaccinated in a new Ebola vaccine trial called Tumaini,” Ghebreyesus wrote. “This trial will help us understand whether any of the vaccine candidates designed for Bundibugyo virus work.”
He further noted that the existing Ervebo vaccine, licensed for use in preventing other Ebola virus disease, will also be tested. “WHO is supporting this DRC-led effort to find answers and save lives,” he added.
Ervebo First to Enter Trial
The first vaccine to enter the trial is Ervebo, which is licensed to prevent Ebola disease caused by the Zaire strain. Researchers will investigate whether it can also offer protection against the Bundibugyo strain responsible for the current outbreak.
Two additional vaccine candidates, being developed by Moderna and the University of Oxford in collaboration with the Serum Institute of India, are expected to join the study.
The trial will evaluate the safety, immune response, and effectiveness of the vaccine candidates. It will also employ a ring vaccination approach, targeting contacts of confirmed cases and other individuals at high risk of infection.
Outbreak Figures and Emergency Declaration
According to figures released by organizations supporting the trial, the DRC had recorded 9,552 cases and 4,602 deaths as of October 21. The outbreak, declared on May 15, 2026, prompted the WHO to declare a Public Health Emergency of International Concern.
The WHO stated that the trial is being led by Congolese health authorities and research institutions, with support from the WHO and international partners.
However, the commencement of the trial does not mean a vaccine has been proven effective against the Bundibugyo strain. The study represents an important step in gathering the scientific evidence needed to determine whether the candidates can provide protection against this specific strain.
Significance of the Trial
The launch of the Tumaini trial underscores the urgency of finding effective countermeasures against the Bundibugyo strain, which has driven the current outbreak. With no approved vaccine for this strain, the clinical trial offers a critical opportunity to evaluate whether existing and emerging vaccine candidates can be adapted to address the threat.
The ring vaccination strategy, which has been used successfully in previous Ebola outbreaks, focuses on immunizing those most likely to come into contact with the virus, thereby creating a protective buffer around confirmed cases. This approach is designed to curb transmission chains and protect vulnerable populations.
The involvement of multiple vaccine developers, including Moderna and the University of Oxford in partnership with the Serum Institute of India, reflects a coordinated international effort to accelerate research and expand the range of potential tools available to public health authorities.
As the trial progresses, health officials and researchers will closely monitor the safety and immune response data generated by the study. The findings will be instrumental in informing future vaccination strategies and determining whether any of the candidates can be deployed at scale to combat the Bundibugyo strain.
The WHO’s support for the DRC-led initiative highlights the importance of local leadership and international collaboration in responding to infectious disease outbreaks. By investing in scientific research and clinical trials during an active outbreak, health authorities aim to build the evidence base needed to protect communities and prevent future crises.